A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety and efficacy of aripiprazole
(initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally
administered over a period of 52 weeks in subjects who complete a short-term treatment study
of pediatric patients (aged 13-17 years) with schizophrenia (031-09-003 study).